AINDEX
Markets

Assembly Biosciences, Inc. (ASMB)

ASMBNASDAQ-GSBiotechnology: Pharmaceutical Preparations

$21.29

+0.1700 (+0.80%) today

Closed, Nov 16, 4:00 PM ET

+0.80% 1D
Market cap
$432.48m
P/E
26.3
EPS, last 4 quarters
$0.8100
Dividend yield
–
Day range
–
52-week range
$19.20 to $39.71
Average volume
–
Previous close
$21.12

Analysts

4 covering

Buy4 buy, 0 hold, 0 sell

Targets a year out average $48.50, +127.8% from here

$43.00now $21.29$53.00

Earnings

next estimate $3.19

Next report

Dec 2025

+586.3%

Mar 2026

+26.0%

Jun 2026

+71.4%

Sep 2026

-111.4%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$42.47m$8.21m$13.37m$2.96m
Gross profit$42.47m$8.21m$13.37m$2.96m
Operating income$19.80m-$11.37m-$6.34m-$23.41m
Net income$22.09m-$9.08m-$3.86m-$20.26m

Last four quarters: revenue $67.01m, margin -16.6%, free cash flow –

News

8 latest

The company

Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesviruses, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV).

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-GS
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.